Medicines Formulary

Medicines A–Z

T

Drug name	NICE TAs	Comments
Temozolomide capsules	TA121 - Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma TA23 - Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Temsirolimus infusion (Torisel®)	TA207 - Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) (Negative TA) TA178 - Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (Negative TA)	Hospital use only
Tenecteplase injection	TA52 - Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction	Hospital use only
Terbinafine 1% cream
Terbutaline
Terbutaline inhaler
Terbutaline nebulised		As an alternative to salbutamol nebules if salbutamol is in short supply
Teriflunomide	TA303 - Teriflunomide for treating relapsing–remitting multiple sclerosis
Teriparatide injection	TA161 - Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Terlipressin injection		Hospital use only

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.